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ABSTRACT
Problem/Purpose: Antibiotic associated diarrhea (AAD) and clostridium-difficile diarrhea
(CDAD) are the most common forms of infectious diarrhea in long-term care facilities. The
purpose of this study was to determine the effectiveness of probiotics in preventing AAD and
CDAD in the long term care geriatric population, and to identify interventions that can be
used to improve clinical practice.
Background/Significance: Prophylactic use of probiotics have been purported to decrease
the incidences of AAD and CDAD. Previous studies have yielded contradictory results on the
efficacy of probiotics. The objective of this study was to evaluate the impact of administration
of probiotics on the rate of infectious diarrhea in the Long Term Care (LTC) population
Method: This was a retrospective cohort study. The charts of residents of a LTC facility who
were 65 years of age and older, and were administered antibiotic therapies, with or without
co-administration of probiotics were reviewed. A data collection instrument was created for
this study and piloted prior to its utilization. A chi-square test of independence was calculated
to obtain the results.
Results: Forty-four residents received probiotics with antibiotics, five cases of diarrhea were
reported; no cases of CDAD were reported. In 39 residents who received antibiotics without
probiotics, two cases of diarrhea and one case of CDAD were reported.
Conclusion: The study showed no statistically significant evidence to support the
effectiveness of probiotic use in the prevention of AAD and CDAD in a long term care
facility. The incidence of AAD was higher in the group with probiotics
ii
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CHAPTER ONE
Probiotics are living organisms, which when ingested have the beneficial therapeutic
effect of reestablishing normal intestinal flora. Each probiotic has its own unique characteristic
and effects. Probiotics belong to several species such as lactobacillus, bifidobacterum,
streptococcus, and yeasts and molds. The probiotics Saccharomyces boulardii, lactobacillus
rhamnosus GG, Lactobacillus plus acidophilus, Lactobacillus bulgaricus, lactobacillus casi and
bifidobacterum bifidium are some of the most frequently used probiotics (Bergogne-Berezin,
2000). Several studies have been conducted over the past 20 years on their effectiveness in the
prevention of antibiotic-associated diarrhea (AAD) and clostridium-difficile diarrhea (CDAD)
with varied results about their effectiveness.
The prevention of AAD and CDAD, or extent of these infections, might assist in the
reduction of morbidity and mortality in the vulnerable geriatric population of long term care
(LTC) facilities. This population is at greater risk of acquiring these infections because of
frequent administration of antibiotics. Other risk factors include comorbid conditions, frailty,
cross infection, age, or congregate living (Schroeder, 2005). CDAD is the most common
infectious cause of diarrhea in LTC residents (Laffan, Greenough, & Zenilman, 2006)
Probiotics are used despite a lack of definitive evidence of their effectiveness in the
prevention of AAD and CDAD in the LTC population. Studies conducted on adult subjects
found that probiotics were effective in the prevention of AAD (Can, BeÅŸirbellioglu, Avci,
Beker, & Pahsa 2006; Gotz, Romankiewicz, Moss, & Murray, 1979; McFarland et al., 1995;
Surawicz et al., 1989). However, two studies found there was no significant benefit of probiotics

in the prevention of AAD and CDAD (Lewis, Potts, & Barry, 1998; Thomas et al., 2001) . Five
meta-analyses on the use of probiotics for the prevention of ADD have been published. These
contained studies that included children. McFarland’s (2006) landmark meta-analysis of 25
randomized controlled trials found that a variety of different types of probiotics have some
therapeutic effect on AAD and CDAD. However, the analysis showed that only three types of
probiotics significantly reduced the development of AAD, and only one was effective for
CDAD. However, none of these study reports provided sufficient data on dosing and duration of
therapy.
Problem/Significance
The widespread use of antibiotics promotes occurrences of diarrheal infections.
Antibiotics disrupt the intestinal microflora which is a protective barrier against the colonization
of intestinal pathogens (Marteau, Vrese, Cellier, & Schrezenmeir, 2001). With the interruption
of this protective barrier, patients become susceptible to opportunistic infections such as AAD
and CDAD (Bergogne-Berezin, 2000; Surawicz, 2003).
AAD can occur during or shortly after antibiotic administration. Even a single dose of
antibiotic can produce an episode of AAD (Katz, 2006). Diagnosis of AAD is made in the
absence of other known causes of diarrhea. Frequency of AAD varies with the type of antibiotic
used and can occur within a day of starting antibiotics or up to six weeks after completion of
antibiotics (Katz, 2006). AAD occurs in 25% of adults receiving antibiotics with rates as high as
26-60% in hospital outbreaks (Katz, 2006; McFarland, 2006).
The World Health Organization defines diarrhea as watery or unformed stools,
occurring more than 3 times a day for at least 2 days. AAD occurs within two months of
2

antibiotic therapy. Risk factors associated with AAD include the use of broad spectrum
antibiotics, such as amoxicillin, second and third-generation cephalosporin, and clindamycin.
Other risk factors include long courses of antibiotic therapy, or repeated courses of antibiotic
therapy, and extremes of age, less than 6 and greater than 65 years (Bergogne-Berezin, 2000).
Additionally, predisposing factors such as history of AAD, serious concomitant disease,
chronic digestive diseases, co-morbidity, and immunodeficiency can precipitate AAD.
Prolonged hospitals stay, surgery, gastrointestinal procedures, nasogastric alimentation and
residing in a nursing home, are all risk factors associated with AAD (Bouhnik, 2006).
CDAD is diagnosed by a positive stool culture for toxin (A or B), stool cytotoxicity
assay positive for Toxin B, or endoscopy for colonic pseudomembranes. CDAD the most
severe form of AAD, accounts for 15% to 25% of AAD and can be very difficult to treat
(Doron, Hibberd, & Gorbach, 2008).
The prevalence of clostridium difficile can range from 2.1% to 8% in LTC facilities
during a one year period (Simor, Yake & Tsimidis, 1993). C-difficile is present in 2-3% of
typically healthy adults and in as many as 70% of normally healthy infants, and is the most
common infectious cause of acute diarrhea in nursing homes (Simor, Yake & Tsimidis, 1993).
Eighty percent of CDAD onset occurs during antibiotic therapy and 8% to 33% of long term care
residents treated with antibiotic therapy acquires infection with CDAD (Simor 2002). Laffan,
Greenough, and Zenilman (2006) in their study found that the incidence of CDAD ranged from 0
to 2.62 cases per 1,000 resident days, with a recurrent rate of 21.7% of patients. Current
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treatment for AAD and CDAD is with the administration of specific antibiotics, metronidazole
and vancomycin.
Probiotics are living organisms (yeast or bacteria) which, when administered in
adequate amounts, have a potentially beneficial therapeutic effect. Some of these are the
prevention of antibiotic-associated diarrhea, decreasing the frequency of recurrent
Clostridium-difficile infection, and preventative and curative activity against acute infectious
diarrhea (McFarland, 1998; Bouhnik, 2006). Several studies found that prophylactic
probiotics are not widely used, although they have been extensively studied (Kopp-Hoolihan,
2001; Sazawal, 2006). There are over 800 publications on probiotics completed to date
(Piche, & Rampal, 2006). However, these research studies conducted on the efficacy of
probiotics provide contradictory results. This may be due to the study designs, type of
probiotic, differing dosage and length of treatment.
There are currently no studies on the effectiveness of prophylactic probiotic
administration, specifically in the LTC geriatric population. Therefore, it is the intent of this
study to obtain information which can direct clinical practice for the use of probiotics as
prophylactic therapy for AAD and CDAD in LTC geriatric population. Overall clinical
practice may be enhanced through the development of evidence to support the use of
probiotics in the LTC geriatric population.

4

Objectives
The objective of this study is to evaluate the effectiveness of probiotics when
administered with antibiotics for the treatment of a variety of infectious diseases with the goal of
preventing of AAD and CDAD. The assumption is that probiotics are effective in the prevention
of AAD and CDAD (Surawicz et al. 1989; McFarland et al., 1995; Bergogne-Berezin, 2000;
Bouhnik, 2006; Can et al. 2006). The incidences and prevalence of AAD and CDAD in the LTC
setting presents a challenge to the health care system as CDAD is the most commonly identified
cause of diarrhea in LTC. Furthermore, as the population ages, concern of infections and
diseases are expected to rise in the LTC population (Laffan et al., 2006). Additionally, there is
sufficient evidence through randomized control trials (RCT) to suggest effectiveness of
probiotics in prevention of these infections. (Gotz et al., 1979; Surawicz et al., 1989; McFarland
et al., 1995; Can et al., 2006).
The design is a retrospective cohort study of a geriatric population in the LTC setting. The
overall aim is to direct clinical practice in the management of AAD and CDAD infections in
this patient population. The geriatric population of LTC facilities includes individuals with
many comorbid conditions, depressed immune systems. Polypharmacy and frequent use of
antibiotics place them at a higher risk of acquiring diarrheal infections.

5

The research questions to be addressed are:
1. Are probiotics effective in preventing AAD and CDAD in the LTC population?
2. Which probiotic dosing is effective in preventing AAD and CDAD?
3. What is the most effective duration of probiotic administered in preventing AAD and
CDAD?

6

CHAPTER TWO
This chapter presents a review of past and current literature on the efficacy of probiotics
in the prevention of AAD and CDAD. Studies included randomized control trials (RCT), metaanalysis and systematic reviews. Eleven studies met the inclusion criteria and are explored in this
chapter.
Antibiotic-associated diarrhea (AAD) is a common problem found in up to 25% of
patients, following the use of antibiotics. Up to 25% of these cases progress to clostridiumdifficile diarrhea (CDAD) (Katz, 2006). The mechanisms underlying AAD include the
proliferation of pathogenic microbes and reduction of fermentative activity on the part of the
microflora (Rambaud, Buts, Corthier & Flourié 2006). The frequent use of antibiotics in the
geriatric population in the long term care (LTC) setting puts them at risk for acquiring these
infections because of age, multiple co-morbidities and immunocompromised state.
Probiotics are purported to be suitable for use in the prevention of these infections
(McFarland 2006) although, several studies have been conducted on the therapeutic benefit of
probiotics without conclusive results (Dunkduri 2005). Currently, use of probiotics is at the
discretion of the prescriber as there are no current guidelines for its use.
Review of Literature
A review of literature was conducted to determine whether the administration of
probiotics along with antibiotic therapy would decrease the incidences of ADD and CDAD in the
geriatric population based on studies conducted to this date. The search terms used were
probiotics, diarrhea, antibiotic clostridium-difficile, evidence based practice, 65+ years, practice
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protocol, clinical trials, humans, and English language. Databases searched included CINAHL,
MEDLINE, PubMed, Cochrane Systemic Review, and Cochrane Central Register of Controlled
Trials. Trials in which probiotics were given for prevention of AAD and CDA were utilized as
the major inclusion criterion for the study. Exclusion criteria for studies were use of probiotics
for treatment of AAD and CDAD, children only studies, and reviews. The articles which met
inclusion criteria included six original studies, four meta-analysis and one systemic review which
provided data on over 5,000 treated patients.
The literature search yielded 302 studies. After limiting the search to studies in which
probiotic were used for prophylaxis of AAD, CDAD, and which were randomized control trials
(RCT), 51 studies were identified and screened for further inclusion. Eleven studies were
selected based on predefined inclusion criteria of studies in which probiotic were used for
prophylaxis of AAD and CDAD, and were randomized control trials (RCT). (see Figure1for
flow diagram of included and excluded studies).
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315 studies identified by electronic
database search

51 studies identified and
screened for inclusion

Antibiotic associated diarrhea
Excluded (n=19), 10 reviews, 3
comparison with antibiotics, 6 not
suitable for inclusion based on
criteria.

Clostridium-difficile
(n=22)
Antibiotic associated
diarrhea (n=29)

Clostridium difficile diarrhea
Excluded (n= 21), 6 reviews, 2 case
studies, 4 antibiotic treatment, 8 not
suitable for inclusion based on
criteria 1 pilot study

11 studies meet inclusion criteria
1 CDAD systematic review
1 AAD and CDAD meta-analysis
3 AAD meta-analysis
6 AAD original studies

Figure 1 Flow diagram of included and excluded studies.

Note: AAD indicate antibiotic associated diarrhea. CDAD indicate clostridium-difficile diarrhea.

Gotz and colleagues (1979) conducted a randomized controlled placebo trial of 98
hospitalized patients’ with ages ranging from 18 to 88 who were treated with Ampicillin and
were also administered Lactobacillus acidophilus and Lactobacillus bulgaricus to determine the
efficacy of these probiotics in the prevention of AAD and CDAD. The patients were treated with
one packet of either Lactobacillus acidophilus, Lactobacillus bulgaricus or placebo four times a
day for the first five days of ampicillin therapy. Data from 79 patients were collected and
reviewed, the results showed that the patients in the ampicillin and placebo group had ampicillin9

induced diarrhea at a rate of 14% (p=0.03) and those in the ampicillin and probiotics group
experienced no diarrhea. This result suggests that prophylactic use of probiotics appears to be
effective in the prevention of AAD.
Surawicz et al. (1989) conducted a randomized controlled placebo trial of 180
hospitalized patients receiving the antibiotics clindamycin, cephalosporins, or trimthoprimsulfamethazole. Subjects were randomized to receive either a placebo or Saccharomyces
boulardii. The study was conducted over a period of 23 months during which time the duration
of antibiotic therapy administration varied. The results showed that 22% of patients receiving
antibiotic and placebo acquired AAD compared to 9.5% of those receiving antibiotic and
probiotic (p=0.038). This result suggests that prophylactic probiotics appear to be effective in the
prevention of AAD.
Another study which showed efficacy of probiotics in the prevention of AAD and CDAD
was conducted by McFarland et al. (1995). In this randomized controlled placebo trial 193
patients were treated with the B-lactam, tetracycline, and the probiotic Saccharomyces boulardii
(1g/day) within 72 hours of the start of antibiotic through to 3 days after completion of the
antibiotic therapy. The patients were followed up for seven weeks after antibiotic therapy.
Fourteen point six percent (14/96) of patients receiving antibiotic and placebo developed AAD
(p=0.02). Whereas 7.2% (7/97) of patients receiving antibiotic and probiotics developed AAD,
with the efficacy of Saccharomyces boulardii in the prevention of AAD being 51%. Suggesting
that Saccharomyces boulardii a probiotic has demonstrated effectiveness in preventing AAD.
Can et al. (2006) recently conducted a randomized controlled placebo trial of 151
hospitalized patients receiving antibiotics. Subjects were randomized to receive either the
10

probiotic Saccharomyces boulardii or a placebo with the antibiotic therapy. The results of this
study showed that 9% (7/78) patients in the antibiotic and placebo group developed AAD and
1.4% (1/73) patients in the antibiotic and probiotics group developed AAD (p=<0.05). On further
evaluation two of seven stool samples collected from the placebo group with AAD tested
positive for CDAD, however, no stool from the probiotic group tested positive for CDAD, which
provides evidence that probiotics is effective in preventing AAD and CDAD when compared
with placebo.
Studies conducted by both Lewis et al., 1998 and Thomas et al., 2001 found no
significant efficacy in the administration of probiotics for the prevention of AAD. Lewis, et
al.(1998) conducted a randomized controlled placebo trial of 69 hospitalized patients who were
prescribed antibiotics and were randomized to receive the probiotic Saccharomyces boulardii
(113 mg) twice a day or placebo during the course of the antibiotic therapy. Their results
showed 17% (5/33) of patients receiving antibiotic and placebo developed CDAD and 21%
(3/36) in the antibiotic and probiotic group developed CDAD. The conclusion of the study was
that efficacy was not shown in favor of probiotics in preventing AAD and CDAD when
compared with placebo.
Thomas et al. (2001) conducted a randomized controlled placebo trial of 267 hospitalized
patients who were administered either Lactobacillus GG (20x109 CFU) one capsule two times a
day and a placebo one two times a day over a 14 day period and monitored for seven days after
completion of the treatment. The results showed that 29.3% (39/133) patients receiving antibiotic
and the probiotic Lactobacillus GG had diarrhea, whereas, 29.9% (40/134) participants receiving
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placebo developed diarrhea. The conclusion of the study was that efficacy was not shown in
favor of probiotics in preventing AAD when compared with placebo.
Three meta-analyses and one systematic review were examined to evaluate the effects of
probiotics in the prevention of diarrhea associated when used in combination with antibiotic.
D’Souza, Rajkumar, Cooke, & Bulpitt (2002) conducted a meta-analysis of nine randomized
placebo-controlled trials covering over 1,300 subjects. The results supported the conclusion that
probiotics can be used in the prevention of AAD, that Saccharomyces boulardii and lactobacilli
have the potential to be used for this infection.
Cremonini, et al. (2002) conducted a meta-analysis of seven randomized placebocontrolled trials covering over 800 subjects. The results supported the conclusion that probiotics
were more effective than placebo in the prevention of AAD. Suggesting administration of
probiotic can have benefit on AAD. However, they concluded that the evidence of beneficial
effects is not very definitive as published studies are flawed by a lack of placebo design and
peculiar population features.
Sazawal, et al. (2006) in their meta-analysis of 19 masked randomized placebocontrolled trials involving over 2, 000 subjects found that six of the studies on prophylactic
probiotic use had statistical significance with an overall reduction of 52% of AAD.
A systematic review of eight randomized controlled trials conducted by Dendukuri,
Costa, McGregor & Brophy (2005) was conducted to identify studies in which the prevention or
treatment of CDAD with probiotic therapy was the primary or secondary outcome. The results
showed that there was insufficient evidence in studies conducted to date to for routine use of
probiotics for the prevention of CDAD.
12

The major meta-analysis of probiotics for the prevention of AAD and treatment of
CDAD was conducted by McFarland (2006). This study examined 31 randomized control trials
which studied the use of probiotics for the prevention of AAD and treatment of CDAD. Twentyfive of these studies reviewed were for the prevention of AAD and involved over 2500 subjects.
The results showed a 44% reduction of AAD in adults, 52% of the studies showed a reduction in
the incidences of AAD compared to placebo, with higher dosing associated with positive
efficacy. Moreover, a variety of probiotics Lactobacillus rhamnosus GG, Saccharomyces
boulardii and probiotic mixtures showed significant efficacy and promise as effective therapies
for the reduction of AAD. The study also found that Saccharomyces boulardii was an effective
treatment for CDAD.
Discussion
Antibiotic-associated diarrhea and CDAD infections are common; but potentially serious
health problems Prevention of these infections is justified as they can be costly for this
population in morbidity and mortality as well as the price of treatment. The restoration or
maintenance of the gut microflora in the presence of antibiotic use is necessary to prevent the
occurrences of these infections. The main original studies on the use of probiotics were not
definitive in the efficacy of probiotics in the prevention of AAD and CDAD. This may be due to
the study’s design, the length of therapy, duration of therapy, follow up period and dosing of
probiotic administered. It is of note however, that the majority of studies did provide evidence of
efficacy. The meta-analysis or systematic review did show that efficacy was evident in the
majority of studies. These studies included children studies and pilot studies.
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Limitations of these studies are that all they were conducted either with hospitalized
patients or outpatient adults or children (specifically the meta-analysis or systematic reviews),
not principally elderly residents in LTC facilities. In conclusion, the studies of the benefits
reported do not adequately include the geriatric population of LTC facilities; therefore, there is a
need to obtain this information. Consequently, the intent is to conduct future studies to
investigate the effectiveness of administering probiotics in this specific population for the
prevention of AAD and CDAD. The results of such a study can contribute knowledge of best
clinical practice in the care of this population.
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CHAPTER THREE
In this chapter, the research design to address the three research questions is discussed.
The three research questions are: 1.Are probiotics effective in preventing AAD and CDAD in
the LTC population? 2. Which probiotic dosing is effective in preventing AAD and CDAD?
3. What is the most effective duration of probiotic administered in preventing AAD and
CDAD? The setting, participants, sampling, human subjects, data collection tool and
procedure are also presented. Data analysis, strengths and limitations of the research design
and plans for future studies are explored.
Research Design
This was a retrospective descriptive cohort study of the effectiveness of probiotics
administration among LTC residents’ ages 65 years and over who were administered antibiotics
with or without probiotics within the past 12 months. The intent of this study was to determine if
the prophylactic use of probiotics was effective in preventing AAD and CDAD.
Strengths
The strengths of retrospective cohort studies are that naturally occurring events can be
studied and the measurement predictor cannot be biased by knowledge of which participants
have the outcome of interest (Hulley, Cummings, Browner, Grady & Newman 2001).
Retrospective cohort studies are less expensive and time consuming than RCTs. The resources
are mainly directed at collection of data only. Additionally, participants have already been
identified, baseline measurements have been made and the follow-up period has already taken
place.
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Limitations
The main limitation of retrospective cohort studies is the restricted control the researcher
has over the design of the approach of sampling the population and the nature and quality of the
predictor variables. The existing data may not include information that is important to answering
the research questions. Data may be incomplete, inaccurate, or measured in ways that are not
ideal for answering the research question (Hulley et al. 2001).
Setting/Participants/Sampling
The study setting was at a LTC facility in Melbourne Florida which has 160 beds, and
various occupancy rates. The participants were a convenience sample of geriatric patients, aged
65 years and older who were residing in the facility for more than six months and were treated
with antibiotics for a period of one day or more, between January 2009 and December 2009.
Data was obtained from a chart review. If a participant received probiotics at the same time as an
antibiotic in any of the commercially available species, lactobacillus, bifidobacterum,
streptococcus and yeasts and molds, in pill, capsule, granule or suspension form, during the 12
month period they were included in the treatment group. The participants who received
antibiotics without probiotics during the 12 month period comprised the control group. The data
on subjects meeting inclusion criteria was obtained from the participants’ facility medical
records. Exclusion criteria included age less than 65 years; reside in the facility less than six
months, i.e. patients who have transitioned from rehabilitation care, and those having a past
medical history of inflammatory bowel disease, such as Chron’s disease, ulcerative colitis or
irritable bowel syndrome.
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Human Subjects
The researcher received permission from the LTC facility to conduct the study. Because
of the retrospective record review design of the study no risk to humans was expected. Approval
to conduct the study was received from the institutional review board (IRB) at the University of
Central Florida prior to the data collection process. The protected health information (PHI) was
kept separate from the patients’ chart identification number.
In order to maintain confidentiality and meet the health insurance portability and
accountability act (HIPAA) requirements, all protected health information (PHI) was deidentified. Elements that can be used to identify a specific person, or the person’s relative,
employer or household members were not collected. Charts were tracked and deidentified by
assigning random numbers to each chart; these numbers were kept in the facility’s medical
record file. A data use agreement between researcher and facility was obtained. (Appendix A).
An approval of exempt human research was obtained from IRB prior to the initiation of the study
(Appendix B).
Data Collection Tool
The data collection tool used to summarize information from the chart review was a
demographic and clinical profile form which captured information about the participants’ age,
gender, length of residency in the LTC facility, chronic medical conditions, and antibiotic
therapy within the period from January 2009 through December 2009. (Appendix C). Probiotic
data collection consists of type of probiotic received, form of probiotic, number of doses per day
and duration of therapy. AAD and CDAD data was defined as three or more loose stool within
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two months after antibiotic therapy, new episode of diarrhea associated with positive culture or
toxin (A or B), positive culture of any other bacteria or virus. Prior to the study a pilot of the data
collection instrument was completed. The principal researcher reviewed a sample of five charts
using the data collection tool. Adjustments were made to the form for easier data recording.
Procedure
Data was collected by the principal investigator. The data was be reviewed to assess for
content validity to determine if the data collected covered a representation of the element to be
measured or if there was additional information pertinent to the study that needed to be
examined.
Data Analysis
Statistical analysis was performed using SPSS software version 17.0 (Statistical Package
for the Social Sciences). The chi-square test of independence analysis was used to test for
statistical significance of the relationship between probiotic use and non probiotic use in the
prevention of AAD and CDAD. The null hypothesis states that there is no difference in
prevention of AAD and CDAD with administration of antibiotics with or without probiotics.
The Cochran’s Q was used to determine if there is a difference in AAD and CDAD rates in
subjects who were administered probiotics in various doses of 1, 2, 4, or 6 doses per day. The
null hypothesis states there is no difference in the dose of probiotics administered and the
prevention of AAD and CDAD.
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CHAPTER FOUR
This chapter provides the results of the study. The demographics and clinical profile of
the participants are provided. This includes age, gender, chronic conditions, and conditions
treated with antibiotics. The types of antibiotics and probiotics used in this population within
the 12 month period are specified.
Results
Data was obtained from electronic computer charting in a single LTC facility. Data was
obtained from the resident’s profile, physician’s orders, nursing notes and eMAR (electronic
medication administration record). Laboratory test results were obtained from archived paper
medical records as they were not available from the electronic computer charts. Data was
analyzed with SPSS 17, analysis included frequencies, crosstabs and Chi-square analysis. One
hundred and ninety-two charts were identified for review. Seventy charts failed to meet
inclusion criteria for one or more reasons. Reasons charts were excluded were that residents
had lived at the facility less than six months (n=54), ages less than 65 (n=15), or the resident
had a pre-existing condition of irritable bowel syndrome (n=1). Other charts which were
excluded were of patients who did not receive either antibiotics or probiotics (n=39) therefore,
83 charts met inclusion criteria.
Sample
Ages of the residents in the final sample ranged from 65 to 106 years, with a mean age of
82 years. There were 56 female (67.5%) and 27 males (32.5%) as illustrated in Table 1. The
most common chronic diseases found in this sample were dementia, chronic pain, constipation,
dysphagia and diabetes mellitus (See Table 2 for common chronic conditions). Sixty-nine of the
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83 subjects had two or more of these chronic conditions. Infections treated with antibiotic
therapy over the 12 month period were often recurrent. These included urinary tract infection
(UTI), upper respiratory infection (URI), skin and soft tissue infection (SSTI), pneumonia and a
variety of other infectious diseases, with urinary tract infection as the most frequently treated
condition (See Table 3 for common conditions treated with antibiotics). Forty-two of the 83 were
treated with antibiotics for two or more infections.
Table 1 Age and Gender Distribution

Characteristics Number %
Age
Mean

82 years

Gender
Male

27

32.5

Female

56

67.5

Table 2 Common Chronic Conditions

Chronic conditions n

%

Diabetes

26 31.3

Constipation

44 52

Chronic pain

47 56.6

Dementia

48 57.8

Dysphasia

38 45.8
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Table 3 Common Conditions Treated with Antibiotics

Conditions

n

%

Urinary tract infection

48 57.8

Pneumonia

11 13.3

Upper respiratory infection

25 30.1

Cellulitis

8

9.6

Skin and Soft tissue infection (SSTI) 17 20.5
Other conditions

24 28.9

Eighty-three residents were administered antibiotics of various classes during the 12
month period of January 1, 2009 to December 31, 2009. Forty-four residents (53%) were
administered probiotic along with antibiotic therapy, whereas 39 (47%) received antibiotics only.
Antibiotics were prescribed and administered a total of 234 times to the 83 residents. While 36
individuals received only one course of antibiotic, many received more than that. In some cases
participants received four or five courses of antibiotics. In one case antibiotic was administered
18 times to a single resident for various infections over the 12 month period. See Table 4 for
summary of frequency of antibiotics prescribed and administered for the full study group.
Various classes of antibiotics were administered. These included quinolones, cephalosporins,
penicillins, macrolides, sulfonamides, tetracyclines and a combination or other classes within the
12 month period. This is illustrated in Table 5.
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Table 4 Frequency of Courses of Antibiotics Prescribed During 12 Month Period of Study

Number of Courses
of Antibiotics
Prescribed

Number of Patients who Received
Indicated Courses of Antibiotic

1

36

2

14

3

11

4

10

5

6

6

1

7

1

8

1

10

1

14

1

18

1
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Table 5 Class of Antibiotics Administered to Patients in the Study

Classification
Cephalosporin
1st Generation

Name

cefalaxin
cefadroxil
nd
2 Generation cefotetan
cefprozil
cefuroxime
3rd Generation ceftriaxone
4th Generation cefepime
trimethoprimSulfonamides
sulfamethoxazole
trimethoprimTetracycline
sulfamethoxazole DS
doxycycline
Quinolones
tetracycline
Aminoglycoside levofloxacin
ciprofloxacin
Penicillin
gentamycin
amoxicillin
ampicillin
amoxicillin/clavlanate
Macrolide
pen-V-K
azythromycin
Other
erythromycin
primaxin
nitrofurantoin
linezolid
clindamycin

Number of Times Prescribed
and Administered

Route of
Administration

15
1
1
1
13
19
1

PO
PO
PO
PO
PO
IM
IV

11

PO

8
16
1
48
36
2
14
5
7
1
19
1
1
11
1
1

PO
PO
PO
PO
PO
IM
PO
PO
PO
PO
PO
PO
IV
PO
PO
PO

Note: PO indicates by mouth. IM indicates intramuscular. IV indicated intravenous .

Probiotic was administered with antibiotic 78 times of the 234 courses of antibiotics
prescribed within the 12 month period. Probiotic was given in various frequencies, forms and
dosing and duration. Duration did not always match duration of the antibiotics. Seventy-six
doses were of various forms of acidophilus, and two were of Saccharomyces boulardii. The most
common forms of probiotics administered were capsules (n=59) and caplets (n=18) Dose of
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probiotic was not noted on many of the records. Frequency of probiotic administration varied.
This is illustrated in Table 6. The duration of probiotic therapy varied. The most frequent
duration of 10 days illustrated in Table 7. The most frequent dosing was one, two times a day
(See Table 8 for frequency of probiotic dosing).
Table 6 Types of Probiotic Used

Type of
Probiotics

Number of
Times Rx

Form of
Probiotics

Doses of
Probiotics

Duration of
Therapy

Prescribed
Amount

Acidophilus

45

Capsules

Unknown

<7 days to 16
days

Acidophilus

18

Caplets

Unknown

Acidophilus
Acidophilus
Pectin
Acidophilus
Saccharomyces
boulardii

06

Capsules

16 mg

< 7 days to
14 days
10 to 14 days

1 Daily; 1
BID; 1 TID;
2 BID
1BID to 2
BID
1 BID

02
03

Capsule
Capsule

Unknown
175 mg

10-14 days
10-14 days

1 BID
1 BID

02

Capsule

250 mg

1 BID

Acidophilus
Acidophilus

01
01

Wafer
Capsule

Unknown
1 mg

<7days-10
days
10 days
10 days

Note: BID indicates two times a day. TID indicates three times a day.

Table 7 Duration of Probiotic Therapy

Duration of Probiotic Number of Times Prescribed
<7 days

5

7 days

10

10 days

52

14 days

10

21 days

0

>21 days

0

Other (16 days)

1
24

1 BID
1BID

Table 8 Frequency of Probiotic Administered

Prescribed Amount Frequency Prescribed
1 Daily

04

1 BID

62

2 BID

08

1 TID

04

2 TID

0

Note: BID indicates two times a day. TID indicates three times a day.

Findings
The occurrence rate of diarrhea episodes found in the 83 residents was 8 (9.6%). There
were five cases of diarrhea in the 44 residents who were administered both antibiotics and
probiotics (11.4%). None of these records had documentation of positive cultures for
clostridium-difficile or other organisms. There were two cases of diarrhea in the 39 residents
who were administered antibiotic without probiotic (5.2%). One subject was positive for
clostridium-difficile toxin A/B (2.6%), after administration of antibiotic without probiotic. The
ages of the residents who had diarrhea ranged from 69 to 97 years. Not all the residents who
had episodes of diarrhea had been administered antibiotic by mouth. Four of the eight residents
had a diagnosis of dysphagia and one had a percutaneous gastrostomy tube (PEG) with which
all medications were administered.
Research Questions
Question One
Are probiotics effective in preventing AAD and CDAD in the LTC population?

25

Data was analyzed with SPSS 17. Analysis was completed using the chi-square test to
compare the relationship of diarrhea rate within two months of antibiotic administration with
probiotics and without probiotics. Antibiotic with probiotic administration had an 11.4% (n=5)
occurrence rate for AAD, whereas antibiotic administered without probiotic had a 5.2% (n=2)
occurrence rate (X²(1) =1.041, p>.308). No statistically significant difference was found
between the numbers of cases of AAD in those who were administered both antibiotics and
probiotics and those who were administered antibiotic without a probiotic. Antibiotic with
probiotic administration had no occurrence of CDAD, whereas antibiotics without probiotics
administration had 2.6% (n=1) occurrence (X²(1) =1.142, p>.285). No statistically significant
difference was found between the number of cases of CDAD in those who were administered
antibiotics and probiotics and those who were administered antibiotic without probiotic (See
Table 9 for results on the effectiveness of prophylactic probiotic use). Therefore, the null
hypothesis which states that there is no difference in prevention of AAD and CDAD with
administration of antibiotics with or without probiotics is supported.
Question Two
Which probiotic dosing is effective in preventing AAD and CDAD?
Data was analyzed with SPSS 17. Analysis was calculated using Cochran’s Q statistical
test to answer this question, however, the variables were not dichotomous, and therefore, the
test could not be performed. Moreover, no effective dosing is found in the study as there were
only two types of probiotics given, one only twice and the other in various forms and dosing;
furthermore, no significant effectiveness of probiotics administration with antibiotic was shown
in preventing AAD and CDAD.
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Question Three
What is the most effective duration of probiotic administered in preventing AAD and CDAD?

Data was analyzed with SPSS 17. Analysis was calculated using Cochran’s Q statistical
test to answer this question, however, the variables were not dichotomous, and therefore, the
test could not be performed.
Table 9 Results on the Effectiveness of Prophylactic Probiotic Use

Drug Administration n (% AAD)

n ( % CDAD)

Conclusion

Antibiotic with
Probiotic

5 (11.4%)

0

No statistically significant evidence found
to conclude relationship between probiotic
use and prevention of AAD and CDAD

Antibiotic without
Probiotic

2 (5.2%)

1 (2.6%)

No statistically significant evidence found
to conclude relationship between probiotic
use and prevention of AAD and CDAD

P-Value

.308

.285
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CHAPTER FIVE
This chapter explores and discusses the study’s findings. The chapter includes limitations
of the study conducted, conclusions and suggestions for further studies to be conducted in the
population of LTC; also, nursing implications are suggested.
Discussion
The findings of this study do not provide evidence to support a relationship between
probiotic use in the prevention of AAD and CDAD. The incidence of AAD was higher in the
group with probiotics by four events.
The results of this study showed no statistically significant evidence to support the
effectiveness of probiotic use in the prevention of AAD or CDAD. Previous randomized control
trial conducted by Gotz et al (1979) found that Lactobacillus acidophilus and Lactobacillus
bulgaricus were effective in preventing AAD in hospitalized patients who were administered
ampicillin therapy versus placebo. Also, Surawicz et al. (1989) in a randomized controlled
placebo study showed efficacy of Saccharomyces boulardii versus placebo in preventing AAD
in patients taking various antibiotics. McFarland et al. (1995) in a randomized controlled placebo
trial and Can et al. (2006) in a randomized controlled placebo study with Saccharomyces
boulardii versus placebo also showed efficacy of probiotic in the prevention of AAD. However,
these studies were conducted in hospitalized patients in a controlled environment with a limited
number of antibiotics and probiotics administered. In this study however, Saccharomyces
boulardii was prescribed and administered on two separate occasions with no occurrences of
AAD or CDAD.
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The results showed that some of the inconstancies found in previous studies were
observed in this study, such as; there were a variety of antibiotics administered at various
frequencies with probiotics administered inconsistently with antibiotic administration. For
example a resident was prescribed antibiotics five separate times during the 12 month period for
various infections and was prescribed probiotics two of the five times an antibiotic was
prescribed. Some of the treatment durations of probiotics were the same as the antibiotic duration
while others were either less than or more than the duration of the antibiotic. This is shown by
the disproportionate number of antibiotics administered (n=234) when compared to the number
of probiotics administered (n=78) illustrated in Figure 4. Therefore there was an overlap in the
treatment group (those who received antibiotic and probiotic) and the control group (those who
received antibiotic only) which may impact the results. The highest number of times a probiotic
was prescribed to an individual resident was three; however, antibiotics were prescribed from
one to 18 times to an individual resident for a variety of infections on different occasions.

Figure 2 Frequencies of Antibiotics and Probiotics Used
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The comparison of earlier studies with this study is complex, as this study is a
retrospective review on the outcome of the administration of prophylactic probiotics to geriatric
patients in a LTC facility. This population has multiple comorbid conditions and frequent use or
administration of antibiotics. This is evident by findings that the study population received
antibiotics on 234 different occasions in a 12 month period, with a range of one to 18 courses of
antibiotic administered per resident.
Various classes of antibiotics were administered over the 12 month period. There were
no controls on the duration, frequency or dosing of probiotic or antibiotic used, as shown by the
various forms and doses of probiotics and antibiotics. Earlier studies were conducted in
hospitalized patients of varying ages from 18 to 88 years of age, whereas, the age range of this
population is 65 to 106 years old, the age difference of the hospitalized patients vary
significantly from those of this study and does not reflect a crucial representation of the LTC
population. Consistent with this study’s findings Lewis et al. (1998) and Thomas et al. (2001), in
their randomized placebo controlled studies also found no significant efficacy of probiotics in the
prevention of AAD.
Limitations
The major limitation of this study is the restricted ability to control the administered
elements (probiotics and antibiotics) to the participants, as this study was a retrospective chart
review. Laboratory tests were not available through the electronic medical record, which
necessitated reviewing the results with archived paper medical records which were not filed by
category. The data presented may be incomplete or inaccurate and not closely monitored for
accuracy. For example the reporting or documenting episodes of diarrhea, or missed doses of
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either antibiotic or probiotic may not have been adequately documented, which can have
significant importance to the results.
In making comparison with earlier studies, the form and duration of probiotics, as well as
the number of times antibiotics were administrated to the participants, ranged from one to 18
courses of antibiotics per resident over the 12-month period. Whereas, earlier studies were
conducted in hospital settings, the route of administration and frequency of administration may
have been more controlled which could produce different results. Some studies reported use of
oral antibiotics and the use of more than one antibiotic during the study. Other factors to be
considered are the chronic conditions of the population with 45.8% of the residents having a
diagnosis of dysphagia; the forms of probiotics were mainly capsule or caplet. This necessitated
modifications prior to administration which may have altered absorption or bioavailability of
antibiotics. This can change the outcome on the effectiveness of the drugs.
Conclusion
This study showed no benefit of probiotic in preventing diarrhea associated with
antibiotic or clostridium-difficile. The assumption is that all available data was accurate and
complete. This study also did not provide answers to the questions:
1. Which probiotic dosing is effective in preventing AAD and CDAD?
2. What is the most effective duration of probiotic administered in preventing AAD and
CDAD?
This study demonstrated that the answers to the questions are difficult or even impossible to be
obtained through retrospective studies if there are inconsistencies in the prescribing of doses
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and duration of therapies. A more tightly controlled prospective study or changes in procedure
related to the documentation of dosing and the consistency of their use may be able to produce
answers to these questions. Additionally, even a longer duration of study may provide answers
to these questions.
The inconsistencies found in this study in which prophylactic probiotics were prescribed
suggest a lack of knowledge on the most effective probiotic dose, frequency or duration and,
possibly, effectiveness of the therapy. Also, the lack of a consensus on the efficacy of probiotic
as shown by previous studies’ contradictory results, may also contribute to these
inconsistencies. There are no current guidelines to direct these practices. There is a lack of
research reported in literature to guide the clinical practice of prophylactic probiotic
administration in LTC; therefore there is a need to conduct ongoing studies in this area so that
healthcare providers can base their treatment decisions on established evidence. Providers in
LTC must be more proactive in observing effectiveness of therapies administered to their
patients to ensure that therapeutic effects are achieved, which can be done through outcomes
research studies and establishment of practice guidelines.
The use of prophylactic probiotics has been studied for over 20 years, some of the studies
were presented in this study, however, there still remain questions that are unanswered, with
regard to LTC population and effectiveness of this therapy. It may be another 20 years before
an answer to the study’s question is determined, hopefully, this will not occur and more studies
in the LTC populations will be conducted to obtain sufficient evidence to establish appropriate
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guidelines. This population is plagued by pill burden and polypharmacy, therefore, safety and
effectiveness of therapies need to be established prior to routine use.
The results of this study did not show effectiveness in the prevention of AAD and CDAD
with the use of prophylactic probiotics co-administered with antibiotics for infectious diseases
in LTC patients. This study is an initial review conducted retrospectively on the effectiveness
of probiotics in preventing AAD and CDAD in the geriatric population. Currently no other
studies were conducted in this area with which to make comparisons. Although, there are
several randomized placebo controlled trials completed in the hospitalized setting with adult
patients which have shown efficacy, these RCTs do not provide adequate representation of the
LTC population.
Implications for Nursing
The results of this study may have provided some evidence to guide the practice of the
administration of prophylactic probiotics in LTC, however, this is an initial study and further
retrospective and prospective studies are needed to provide sufficient evidence on the
administration of probiotics for prevention of AAD and CDAD. The lack of well designed
studies in this population and studies about the efficacy of therapies may be a reason why
probiotics are prescribes inconsistently. There is a need to demonstrate efficacy of a drug prior to
use in these and all other patients. Although studies shows that AAD occurs in 25% of adults
receiving antibiotics and the prevalence of CDAD ranges from 2.1% to 8% in long term care
facilities during a one year period (Katz, 2006: Simor, Yake & Tsimidis, 1993), other proven
measures of prevention and control need to be considered.
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Previous studies found that higher dosing and longer duration of probiotic therapy
resulted in treatment efficacy. As observed in this study the lack of standardization of probiotics
preparations may also contribute to ineffectiveness as dosing may be subtherapeutic. The form
of probiotics may have been altered for administration as 45.8% of the patients had a diagnosis
of dysphagia, which may also have contributed to subtherapeutic dosing. Therefore, it is of great
importance for nurse practitioners and other prescribers to specifically order types, forms,
dosings, and frequencies of drugs, to consider the abilities of the patient to swallow the drugs.

Given that this study is limited to one LTC facility and the sample size is a small
representation of the geriatric population, it would be of great importance to conduct further
studies which can add to an evidenced based clinical practice.

The LTC population is at risk for infectious diarrhea based on the widespread use of
antibiotic therapy as shown in this study. A few previous studies support the use of prophylactic
probiotic therapy to decrease incidences of infectious diarrhea. However, this study found no
evidence which supports these findings. This is an initial study to review the effectiveness of
probiotics in the LTC geriatric population, it is recommended that further studies are conducted
in the geriatric population of LTC facilities before recommendation for use of probiotics
prophylactic for AAD and CDAD is specified.
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LETTER OF APPROVAL FOR STUDY
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APPENDIX B
IRB LETTER OF APROVAL FOR STUDY
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APPENDIX C
DATA COLLECTION TABLE
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Participant number ____________________ Date _________________ Age ________________
B. Gender: □ Male

□ Female

C. Date of admission ______________________

D. Unit _______________________

E. Chronic medical conditions:
1.

8.

2.

9.

3.

10.

4.

11.

5.

12.

6.

13.

7.

14.

15. Irritable bowel syndrome □ Yes □ No

16. Colitis □ Yes □ No

17. Chron’s Disease □ Yes □ No
F.

Antibiotic administration: □ Yes □ No

H. Name of Antibiotic _____________________
J.

G. Class of antibiotic____________________
I.

Duration of Therapy __________________

Diagnosis for Antibiotic Therapy: Circle all that apply
1.

Urinary Tract I infection

2.

Pneumonia

3.

Upper Respiratory Infection

4.

Cellulitis/Soft Tissue Infection

5.

Other/list:

40

K. Probiotic Administered □Yes □ No
L. List all Probiotic Used
1.

5.

2.

6.

3.

7.

4.

8.

M. Duration Probiotic

Form of probiotic

< 7 days

Pill

7 days

Granule

10 days

Capsule

14 days

Suspension

21 days
> 21 days
Other list: 
N. Dose of probiotic
1/day

2/day

4/day

6/day

Other:
Diarrhea > 3 loose stools/day within 2 months of antibiotic therapy: □ Yes □ No
C-diff new episode of diarrhea associated with positive culture or toxin (A or B): □ Yes □ No
Positive Culture of other stool: □ Yes □ No O. Results _____________________________
Comments:
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To: Administrator of West Melbourne Health and Rehab Center
Subject: Request for permission to conduct research study at your facility
Proposal Title: Efficacy of probiotics in decreasing the incidences of antibiotic associated
diarrhea and clostridium difficile.
Introduction:
Prophylactic use of probiotics have been purported to decrease the incidences of
Antibiotic associated diarrhea (AAD) and clostridium-difficile diarrhea (CDAD). The purpose
of this review is to evaluate the efficacy of probiotics in preventing AAD and CDAD. There is
sufficient data presented from previous studies to support the use of probiotics for prevention of
AAD and CDAD.
Nature and Purpose:
The study will involves chart review of LTC residents specifically to determine the
effectiveness of probiotics in decreasing or preventing antibiotic associated diarrhea and
clostridium-difficile associated diarrhea. The information on the effect of probiotics will
provide information on the current practice patterns for prescribing probiotics to LTC
residents, the most effective therapeutic dosing regimen, the most successful therapy duration.
It will provide information which will contribute to implementation of an evidenced based
clinical practice to support improving the quality of life in the LTC population.
Methodology and Expected Results
A review of charts of the residents of the facility would be conducted. The number of charts
to be reviewed would be the number of residents residing in the facility during the period of
January 2009 through December 2009. Only chart of residents’ ages sixty five and older, which
were treated with antibiotic therapy, with or without administration of probiotics would be
reviewed. Instruments to be employed include LTC facility charts and medical records and a data
collection form.
Timeline for study:
January-April 2010: Collect and compile data
May-July 2010: Write formal paper on the results of study.
Thank you for considering my application. I believe that the results of this study will benefit
both the residents and staff of your facility.
Marva Edwards-Marshall ARNP ANP-BC
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Table 10 Synthesis of Literature Review on Efficacy of Probiotics.
Authors

Probiotics

Patients

Number of
patients

Antibiotic

Duration
of
treatment
Variable

Findings
(%
diarrhea)
8.3% vs.,
21%
placebo

P value

Conclusion

Gotz et al
(1979)

Hospitalized

98

Ampicillin

Surawicz et
al. (1989)

Lactobacillus
acidophilus
Lactobacillus
bulgaricus
Saccharomyces
boulardii

P=0.03

Probiotics effective in
prevention of AAD.

Hospitalized

180

Clindamycin
Cephalosporins,
trimthoprimsulfamethazole
Various

Variable

9.4% vs.
31%
placebo

P=0.07

Probiotics effective in
prevention of AAD.

Lewis et al
(1998)

Saccharomyces
boulardii

Hospitalized

69

14 days

Not Stated

193

B-lactam
tetracycline

Variable

Probiotics show no
effect in prevention of
AAD
Probiotics effective in
prevention of AAD.

Hospitalized

302

Various

Variable

Hospitalized

151

Various

Variable

21% vs.
17%
placebo
7.2 %vs.
14.6 %
placebo
29.3% vs.
29.9%
placebo
1.4% vs.
9% placebo

McFarland
et al. (1995)

Saccharomyces
boulardii

Hospitalized

Thomas et
al. (2001)

Lactobacillus GG

Can et al
(2006)

Saccharomyces
boulardii
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P=0.02

P=0.93

P=<0.05

Probiotics show no
effect in prevention of
AAD.
Probiotics effective in
prevention of AAD.

Table 11 Synthesis of Meta-Analysis and Systematic Reviews on Efficacy of Probiotics.
Authors
McFarland

Pub
Yr
2006

Purpose

Findings

Conclusion

31 RCT studies were used to
evaluate the prevention of AAD
and treatment of CDAD.
Sample size for AAD studies
(n=25) with >2,800 subjects.

Adults with 44% reduction in
AAD in probiotic group.
52% studies showed a
significant reduction in the
incidences of AAD compared
to placebo group.

Probiotics were effective in the
prevention of AAD.

D’Souza
et.al

2002

Randomized placebo-controlled
meta-analysis study on the
prevention of AAD with probiotic
use.
Sample size (n=9) studies, with
>1300 subjects.

Probiotics more effective at
preventing incidences of AAD
than placebo.

In all nine trials, probiotics
were given in combination
with antibiotics. Results of this
study suggest that probiotics
were effective in preventing
antibiotic diarrhea. With
significance of P<.001.

Sazawal, et.
al.

2006

Randomized, placebo-controlled
trials were used to evaluate the
effectiveness of probiotics in the
prevention of AAD
Sample size (n=6) using > 2000
subjects

Overall reduction of 52% in
AAD in the probiotic group.

Dendukuri
et. al.

2005

Insufficient evidence on the
effectiveness of probiotics in
preventing CDAD.

Cremonini
et. al.

2002

4RCT studies were used to evaluate
the effectiveness of probiotics in
the prevention of CDAD
Sample size (n=4) involving
Randomized placebo-control
studies were used to determine the
efficacy of probiotics in prevention
of AAD.
Sample size (n=7) with > 800
subjects.

Overall the risk ratios was
0.65, which is significant and
suggests that probiotics is
effective in preventing AAD.
Some of the studies the results
were more significant than
others, however overall
efficacy was significant.
Probiotics were not shown to
be effective in preventing
CDAD.

52% overall reduction in the
probiotics group for AAD.
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The RR of 0.3966 indicates a
strong benefit of probiotics for
prevention of AAD.
Studies not exclusive to
geriatrics.
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